Last reviewed · How we verify
peg-IFN alpha -2a
peg-IFN alpha -2a is a Small molecule drug developed by French Innovative Leukemia Organisation. It is currently in Phase 1 development. Also known as: Pegasys.
Peg-IFN alpha-2a is used to treat conditions such as Hepatitis C and Chronic Hepatitis C Virus, as indicated by ClinicalTrials.gov. The mechanism of action of peg-IFN alpha-2a is not specified in the provided facts, but according to ChEMBL, it is an interferon that works by binding to the interferon-alpha receptor, which triggers a signaling cascade that activates immune responses.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | peg-IFN alpha -2a |
|---|---|
| Also known as | Pegasys |
| Sponsor | French Innovative Leukemia Organisation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Peg-interferon for Inactive Chronic Hepatitis B Carriers (PHASE2, PHASE3)
- A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg (PHASE1, PHASE2)
- Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis (NA)
- Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (PHASE2)
- Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- peg-IFN alpha -2a CI brief — competitive landscape report
- peg-IFN alpha -2a updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI
Frequently asked questions about peg-IFN alpha -2a
What is peg-IFN alpha -2a?
Who makes peg-IFN alpha -2a?
Is peg-IFN alpha -2a also known as anything else?
What development phase is peg-IFN alpha -2a in?
Related
- Manufacturer: French Innovative Leukemia Organisation — full pipeline
- Also known as: Pegasys
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing